- Teva Pharmaceutical Industries Ltd.
- Actavis Laboratories
- Ivax Corp.
- Mylan NV
- Watson Laboratories Inc.
- Allergan PLC
- Barr Laboratories Inc.
- Impax Laboratories Inc.
- Novartis AG
- Geneva Pharmaceuticals Inc.
- Lek DD
- Novartis Pharma AG
- Merck & Co. Inc.
- Schering-Plough Corp.
- Bristol-Myers Squibb Co.
- Aventis SA
- Teva Women's Health Inc.
- Cardinal Health Inc.
- DuPont Pharmaceuticals Co.
- Eastern Virginia Medical School
- Oclassen Pharmaceuticals Inc.
- Pharmacia Corp.
- Genelabs Technologies Inc.
- Somerset Pharmaceuticals Inc.
- Alza Corp.
- Johnson & Johnson
- Pfizer Inc.
- Eli Lilly & Co.
- Enhance Pharmaceuticals Inc.
- Solvay SA
- Solvay Pharmaceuticals Inc.
- Teva Neuroscience Inc.
- H. Lundbeck AS
- Forest Laboratories Inc.
- Sunovion Pharmaceuticals Inc.
- InterMune Inc.
- Novartis acquires Lek
- Barr buys Duramed
- DuPont and Barr team up; deal restructured with BMS
- Bristol-Myers Squibb buys DuPont Pharma for $7.8bn
- Barr Labs licenses East Virginia Med School contraceptive
- Watson acquires Oclassen for $135mm
- Watson buys US rights to 3 Searle contraceptives for $120mm
- Watson licenses NA rights to Genelab's lupus drug
- Watson to buy drug delivery company TheraTech in stock swap
- Watson to acquire Schein Pharmaceuticals for $674mm
- Pfizer acquires Pharmacia in $59bn all stock deal
- Barr Laboratories acquires Enhance Pharmaceuticals for $45mm
- Duramed and Solvay co-promote hormones
- Marion Merrell Dow will market Copaxone with Teva Pharma.
- Teva buys Teva Marion interest from Aventis
- Hoechst Marion Roussel to market Teva's MS drug
- Lundbeck licenses two Teva Parkinson's disease drugs
- Lundbeck, Teva to develop and market oral drug for MS
- Sepracor raises $500mm through convertible debt placement
- InterMune nets $129mm in FOPO
- InterMune nets $144.4mm in notes offering
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.